Department of Chemistry, University at Buffalo, The State University of New York, Amherst, NY 14260, USA.
Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, NY 14263, USA.
Molecules. 2020 May 13;25(10):2291. doi: 10.3390/molecules25102291.
Complexes of Fe(III) that contain a triazacyclononane (TACN) macrocycle, two pendant hydroxyl groups, and a third ancillary pendant show promise as MRI contrast agents. The ancillary group plays an important role in tuning the solution relaxivity of the Fe(III) complex and leads to large changes in MRI contrast enhancement in mice. Two new Fe(III) complexes, one with a third coordinating hydroxypropyl pendant, Fe(L2), and one with an anionic non-coordinating sulfonate group, Fe(L1)(OH), are compared. Both complexes have a deprotonated hydroxyl group at neutral pH and electrode potentials representative of a stabilized trivalent iron center. The r relaxivity of the Fe(L1)(OH) complex is double that of the saturated complex, Fe(L2), at 4.7 T, 37 °C in buffered solutions. However, variable-temperature O-NMR experiments show that the inner-sphere water of Fe(L1)(OH) does not exchange rapidly with bulk water under these conditions. The pendant sulfonate group in Fe(L1)(OH) confers high solubility to the complex in comparison to Fe(L2) or previously studied analogues with benzyl groups. Dynamic MRI studies of the two complexes showed major differences in their pharmacokinetics clearance rates compared to an analogue containing a benzyl ancillary group. Rapid blood clearance and poor binding to serum albumin identify Fe(L1)(OH) for development as an extracellular fluid contrast agent.
含有三氮杂环壬烷(TACN)大环、两个悬垂羟基和第三个辅助悬垂基团的 Fe(III) 配合物有望成为 MRI 造影剂。辅助基团在调节 Fe(III) 配合物的溶液弛豫率方面起着重要作用,并导致小鼠 MRI 对比增强的巨大变化。两种新的 Fe(III) 配合物,一种具有第三个配位的羟丙基悬垂基团 Fe(L2),另一种具有阴离子非配位的磺酸盐基团 Fe(L1)(OH),进行了比较。这两种配合物在中性 pH 值下均具有一个去质子化的羟基,并且电极电位代表稳定的三价铁中心。在 4.7 T、37°C 的缓冲溶液中,Fe(L1)(OH) 配合物的 r 弛豫率是饱和配合物 Fe(L2)的两倍。然而,变温 O-NMR 实验表明,在这些条件下,Fe(L1)(OH) 的内球水不会与体相水快速交换。与含有苄基的 Fe(L2)或之前研究的类似物相比,Fe(L1)(OH) 中的悬垂磺酸盐基团赋予了该配合物高的溶解度。两种配合物的动态 MRI 研究表明,与含有苄基辅助基团的类似物相比,它们在药代动力学清除率方面存在显著差异。快速的血液清除和与血清白蛋白的不良结合表明,Fe(L1)(OH) 适合开发为细胞外液造影剂。